These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24967820)

  • 21. Pleiotropic effects of GIP on islet function involve osteopontin.
    Lyssenko V; Eliasson L; Kotova O; Pilgaard K; Wierup N; Salehi A; Wendt A; Jonsson A; De Marinis YZ; Berglund LM; Taneera J; Balhuizen A; Hansson O; Osmark P; Dunér P; Brøns C; Stancáková A; Kuusisto J; Bugliani M; Saxena R; Ahlqvist E; Kieffer TJ; Tuomi T; Isomaa B; Melander O; Sonestedt E; Orho-Melander M; Nilsson P; Bonetti S; Bonadonna R; Miccoli R; Delprato S; Marchetti P; Madsbad S; Poulsen P; Vaag A; Laakso M; Gomez MF; Groop L
    Diabetes; 2011 Sep; 60(9):2424-33. PubMed ID: 21810601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
    Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
    Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways.
    Friedrichsen BN; Neubauer N; Lee YC; Gram VK; Blume N; Petersen JS; Nielsen JH; Møldrup A
    J Endocrinol; 2006 Mar; 188(3):481-92. PubMed ID: 16522728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biology of incretins: GLP-1 and GIP.
    Baggio LL; Drucker DJ
    Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
    Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel extrapancreatic effects of incretin.
    Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice.
    Tura A; Pacini G; Yamada Y; Seino Y; Ahrén B
    Am J Physiol Regul Integr Comp Physiol; 2019 Jan; 316(1):R27-R37. PubMed ID: 30462524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.
    Drucker DJ
    Diabetes; 2013 Oct; 62(10):3316-23. PubMed ID: 23818527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin actions beyond the pancreas: lessons from knockout mice.
    Yabe D; Seino Y
    Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
    Sridhar A; Khan D; Flatt PR; Moffett CR; Irwin N
    Peptides; 2023 Nov; 169():171093. PubMed ID: 37660881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?
    Whalley NM; Pritchard LE; Smith DM; White A
    J Endocrinol; 2011 Oct; 211(1):99-106. PubMed ID: 21795304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Atageldiyeva KK; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Diabetologia; 2016 Mar; 59(3):533-41. PubMed ID: 26693710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival.
    Khan D; Vasu S; Moffett RC; Irwin N; Flatt PR
    Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):749-758. PubMed ID: 28069397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.
    Yang H; Wang S; Ye Y; Xie M; Li Y; Jin H; Li J; Gao L
    Neuropeptides; 2021 Feb; 85():102110. PubMed ID: 33307381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
    Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
    Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.
    Preitner F; Ibberson M; Franklin I; Binnert C; Pende M; Gjinovci A; Hansotia T; Drucker DJ; Wollheim C; Burcelin R; Thorens B
    J Clin Invest; 2004 Feb; 113(4):635-45. PubMed ID: 14966573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.